HIV-1 drug resistance resulting from antiretroviral therapy far exceeds that from pre-exposure prophylaxis

Clinical Infectious Diseases

Volumn 55, Issue 2, 2012, Pages 303-304

  Parikh, Urvi M ^a   Mellors, John W ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; TENOFOVIR;

ANTIBIOTIC RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PRE EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; PROPHYLAXIS; TREATMENT FAILURE;

ANTI-HIV AGENTS; CHEMOPREVENTION; DRUG RESISTANCE, VIRAL; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE;

EID: 84864153212     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis373     Document Type: Letter

References (10)

1. Hurt CB, Eron JJ Jr, Cohen MS. Preexposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clin Infect Dis 2011; 53:1265-70.
2. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-74.
3. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-99.
4. Thigpen MC, Kebaabetswe PM, Smith DK, et al. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in botswana: results from the tdf2 study abstract welbc01. In: Program and abstracts of the 6th IAS Conference on HIV Pathogenesis, Treatment, and Prevention (Rome, Italy). Geneva, Switzerland: International AIDS Society, 2011.
5. Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 2010; 10:155-66.
6. Singh A, Sunpath H, Green TN, et al. Drug resistance and viral tropism in HIV-1 subtype C-infected patients in KwaZulu-Natal, South Africa: implications for future treatment options. J Acquir Immune Defic Syndr 2011; 58:233-40.
7. Chan M, Sidibe M, Lake A. Global HIV/AIDS response: epidemic update and health sector progress towards universal access-progress report 2011. Available at: http://www.who.int/hiv/pub/progress-report2011/en/.
8. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 2008; 13(Suppl 2):1-13. (Pubitemid 352019085)
9. Hamers RL, Wallis CL, Kityo C, et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 2011; 11:750-9.
10. Komatsu R, Korenromp EL, Low-Beer D, et al. Lives saved by Global Fund-supported HIV/AIDS, tuberculosis and malaria programs: estimation approach and results between 2003 and end-2007. BMC Infect Dis 2010; 10:109.